Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Dermatology · Basal Cell Carcinoma

Standard of Care and Treatment Options

At a Glance

Basal cell carcinoma treatment depends on the tumor’s risk, microscopic type, size, and location. Surgery is common; Mohs can preserve healthy skin for high-risk tumors, while creams, radiation, or medicines may be used for selected or advanced cases.

Deciding on the right treatment for Basal Cell Carcinoma (BCC) depends on a combination of factors: how “risky” the tumor is, its histology, and where it is located on your body. Your care team uses these details to choose the method that offers the highest cure rate while preserving as much healthy skin as possible [1][2].

Treatment Options Comparison

Treatment Typical Candidates Procedure / Duration Expectations & Limitations
Standard Excision Low-risk tumors on trunk/limbs; selected higher-risk lesions if wide margins are safe. Surgical removal with predefined margins. Takes <1 hour. High cure rate for appropriate lesions. Leaves a linear scar. Margins checked after surgery.
Mohs Surgery High-risk, recurrent, H-zone (face/ears), or aggressive subtypes. Surgeon removes tissue in stages, checking 100% of margins under a microscope immediately. Highest cure rate for high-risk tumors; spares healthy tissue. Can take several hours.
Curettage & Electrodesiccation (C&E) Strictly for carefully selected, biopsy-confirmed low-risk, superficial or small nodular tumors. Scraping the tumor and using heat to destroy remaining cells. Quick. Leaves a round, often white scar. Not for hairy areas or aggressive subtypes.
Topical Therapy (Imiquimod/5-FU) Strictly for selected superficial low-risk BCCs. Patient applies cream at home for several weeks. No surgery, but skin gets red and inflamed. Requires strict follow-up to ensure complete clearance.

Low-Risk Treatment Options

For tumors that are small, well-defined, and located in lower-risk areas (like the trunk or limbs), several effective options exist:

  • Standard Surgical Excision: The surgeon cuts out the tumor along with a margin of healthy-looking skin (often 4mm for carefully selected small, low-risk tumors, though margins vary) [3]. The skin is then stitched together. In study populations for low-risk sites, this method is highly successful [4].
  • Curettage and Electrodesiccation (C&E): Often called “scrape and burn,” the doctor uses a sharp tool (curette) to scrape away the soft cancer cells and then uses an electric needle to kill any remaining cells and control bleeding [5]. It is a quick procedure and does not require stitches, but success depends heavily on the doctor’s experience, and it is generally inappropriate for aggressive, recurrent, or cosmetically sensitive sites [6].
  • Topical Therapies: For carefully selected superficial BCCs, creams like imiquimod or 5-fluorouracil (5-FU) can be used. These work by boosting your immune system or directly attacking cancer cells [7]. While they avoid surgery, they require strict adherence and surveillance to ensure complete clearance [8].

High-Risk and “Area H” Treatment: Mohs Surgery

If your tumor is in a high-risk area (the “Mask” of the face, ears, or hands), has aggressive features under the microscope, or has recurred, Mohs Micrographic Surgery is frequently a preferred approach [2][9].

Unlike standard surgery, a Mohs surgeon removes the cancer in stages and examines 100% of the tissue edges under a microscope while you wait [10].

  • Precision: Because the surgeon checks the margins immediately, they only remove what is necessary, sparing more healthy skin than standard surgery [11].
  • Cure Rate: Mohs offers very high success rates for high-risk BCC, with low 5-year recurrence rates (e.g., around 3% in large cohorts) for primary tumors [12]. However, standard excision with appropriate margin assessment or complete margin control can also be an option depending on the case.

Options for Advanced or Unresectable BCC

In rare cases where a tumor is too large for routine surgery, where surgery would cause unacceptable functional harm, or where it has spread (metastatic), other treatments are used via multidisciplinary assessment:

  1. Radiation Therapy: High-energy X-rays can be used to kill cancer cells. It is a primary option for patients who cannot undergo surgery. It can also be used as an adjuvant (add-on) treatment if the margins aren’t clear and re-excision is not feasible, or if there is extensive nerve or bone involvement [13][14].
  2. Hedgehog Inhibitors (Vismodegib, Sonidegib): These are oral pills that target the biological “switch” (the Hedgehog pathway) that tells BCC cells to grow [15]. They can shrink large tumors for locally advanced disease [16][17]. Safety note: These drugs are strongly teratogenic (can cause birth defects) and require strict pregnancy precautions. Side effects like muscle cramps, hair loss, and taste changes are common [18][19].
  3. Immunotherapy (Cemiplimab): This is an IV treatment that helps your immune system find and destroy cancer cells [20]. It is typically used if Hedgehog inhibitors don’t work or cause too many side effects, but it requires careful monitoring for immune-mediated toxicities [21].

Choosing Your Path

Your treatment plan should follow a shared decision-making discussion based on your diagnosis:

  • Is it Low-Risk Superficial? → You might discuss Topicals or C&E.
  • Is it Low-Risk (Trunk/Limbs)? → You might discuss Standard Excision.
  • Is it High-Risk (Face/Nose/Ears/Aggressive)? → Ask whether Mohs Surgery or another complete margin-control approach is appropriate.
  • Is it unresectable? → Multidisciplinary review for Radiation or systemic therapies.

Common questions in this guide

How do doctors choose the best treatment for basal cell carcinoma?
Doctors consider the tumor’s risk level, microscopic type, size, location, whether it has returned, and how much healthy skin can be preserved. Your overall health and preferences about scarring, treatment time, and side effects may also affect the decision.
When is Mohs surgery recommended for basal cell carcinoma?
Mohs surgery is often considered for high-risk tumors, recurrent cancers, aggressive types, and tumors in areas such as the face, ears, or hands. The surgeon removes the tumor in stages and checks the tissue edges immediately, which can help preserve healthy skin while confirming that the margins are clear.
Is standard excision effective for low-risk basal cell carcinoma?
Standard excision is commonly used for appropriately selected low-risk tumors on the trunk or limbs. The surgeon removes the tumor with a margin of surrounding skin, and the edges are checked after surgery; a linear scar is expected.
Can a basal cell carcinoma be treated with a cream?
Selected superficial, low-risk basal cell carcinomas may be treated with imiquimod or 5-fluorouracil cream. Treatment usually lasts several weeks, can cause redness and inflammation, and requires follow-up to confirm that the cancer has cleared.
What is curettage and electrodesiccation for basal cell carcinoma?
Curettage and electrodesiccation involves scraping away the tumor and using heat to destroy remaining cancer cells. It is a quick option only for carefully selected, biopsy-confirmed low-risk superficial or small nodular tumors and is generally not used for aggressive tumors, recurrent cancers, hairy areas, or cosmetically sensitive sites.
What treatments are available for advanced or unresectable basal cell carcinoma?
When surgery is not possible or would cause unacceptable harm, a multidisciplinary team may consider radiation therapy or medicines that target the Hedgehog pathway, such as vismodegib or sonidegib. Cemiplimab may be used when a Hedgehog inhibitor does not work or causes difficult side effects.
What side effects can occur with Hedgehog inhibitors for basal cell carcinoma?
Vismodegib and sonidegib commonly cause side effects such as muscle cramps, hair loss, and taste changes. These medicines can cause birth defects, so strict pregnancy precautions are required.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on skin basal cell carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my 'risk level', which treatment option do you believe offers me the highest chance of long-term cure?
  2. 2.If we choose standard excision or C&E, what is the estimated risk of the cancer coming back in this specific location?
  3. 3.Am I a candidate for Mohs surgery, and would it help preserve more healthy skin in this area compared to standard excision?
  4. 4.If we consider topical creams, how will we monitor the site to ensure the cancer is completely gone?
  5. 5.For advanced options like Hedgehog inhibitors, what are the most common side effects I should prepare for?

References

References (21)
  1. 1

    Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

    Bichakjian CK, Olencki T, Aasi SZ, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2016; (14(5)):574-97 doi:10.6004/jnccn.2016.0065.

    PMID: 27160235
  2. 2

    Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods.

    Kauvar AN, Cronin T, Roenigk R, et al.

    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2015; (41(5)):550-71 doi:10.1097/DSS.0000000000000296.

    PMID: 25868035
  3. 3

    Surgical treatment of basal cell carcinoma: an algorithm based on the literature.

    Luz FB, Ferron C, Cardoso GP

    Anais brasileiros de dermatologia 2015; (90(3)):377-83.

    PMID: 26131869
  4. 4

    Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial.

    Williams HC, Bath-Hextall F, Ozolins M, et al.

    The Journal of investigative dermatology 2017; (137(3)):614-619 doi:10.1016/j.jid.2016.10.019.

    PMID: 27932240
  5. 5

    Beyond the scalpel: rare and experimental nonsurgical treatments for basal cell carcinoma.

    Deng E, Khachemoune A

    Dermatology online journal 2026; (31(6)) doi:10.25251/z041c253.

    PMID: 42246346
  6. 6

    Nonsurgical Options for the Treatment of Basal Cell Carcinoma.

    Paoli J, Gyllencreutz JD, Fougelberg J, et al.

    Dermatology practical & conceptual 2019; (9(2)):75-81 doi:10.5826/dpc.0902a01.

    PMID: 31106008
  7. 7

    A review of emerging and non-US FDA-approved topical agents for the treatment of basal cell carcinoma.

    Kash N, Silapunt S

    Future oncology (London, England) 2021; (17(23)):3111-3132 doi:10.2217/fon-2020-1147.

    PMID: 34156307
  8. 8

    Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma.

    Jansen MHE, Mosterd K, Arits AHMM, et al.

    The Journal of investigative dermatology 2018; (138(3)):527-533 doi:10.1016/j.jid.2017.09.033.

    PMID: 29045820
  9. 9

    Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA).

    Xu YG, Lim Y, Bordeaux JS, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(9)).

    PMID: 39536442
  10. 10

    Favourable results of Mohs micrographic surgery for basal cell carcinoma.

    Gniadecki R, Glud M, Mortensen K, et al.

    Danish medical journal 2015; (62(12)):A5171.

    PMID: 26621396
  11. 11

    Mohs micrographic technique in high-risk basal cell carcinoma: a 3D prediction of safety margins.

    Cammarata E, Esposto E, Airoldi C, et al.

    Journal of wound care 2024; (33(Sup8a)):cxciv-cxcviii doi:10.12968/jowc.2020.0322.

    PMID: 39163154
  12. 12

    10 Years of Mohs Micrographic Surgery in Denmark: Results from a Nationwide Cohort.

    Andersen YMF, Karmisholt K, Høgsberg T, et al.

    Acta dermato-venereologica 2025; (105()):adv41118 doi:10.2340/actadv.v105.41118.

    PMID: 39791512
  13. 13

    Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline.

    Likhacheva A, Awan M, Barker CA, et al.

    Practical radiation oncology 2020; (10(1)):8-20 doi:10.1016/j.prro.2019.10.014.

    PMID: 31831330
  14. 14

    Management of BCC and SCC of the Head and Neck.

    Strom TJ, Caudell JJ, Harrison LB

    Cancer control : journal of the Moffitt Cancer Center 2016; (23(3)):220-7 doi:10.1177/107327481602300305.

    PMID: 27556662
  15. 15

    Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment.

    Dessinioti C, Stratigos AJ

    Dermatology practical & conceptual 2023; (13(4)) doi:10.5826/dpc.1304a252.

    PMID: 37992360
  16. 16

    Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.

    Sekulic A, Migden MR, Lewis K, et al.

    Journal of the American Academy of Dermatology 2015; (72(6)):1021-6.e8.

    PMID: 25981002
  17. 17

    Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.

    Dummer R, Guminksi A, Gutzmer R, et al.

    The British journal of dermatology 2020; (182(6)):1369-1378 doi:10.1111/bjd.18552.

    PMID: 31545507
  18. 18

    Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.

    Basset-Seguin N, Hauschild A, Grob JJ, et al.

    The Lancet. Oncology 2015; (16(6)):729-36.

    PMID: 25981813
  19. 19

    Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

    Migden MR, Guminski A, Gutzmer R, et al.

    The Lancet. Oncology 2015; (16(6)):716-28.

    PMID: 25981810
  20. 20

    Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.

    Gutzmer R, Solomon JA

    Targeted oncology 2019; (14(3)):253-267 doi:10.1007/s11523-019-00648-2.

    PMID: 31243642
  21. 21

    Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.

    Stratigos AJ, Sekulic A, Peris K, et al.

    The Lancet. Oncology 2021; (22(6)):848-857 doi:10.1016/S1470-2045(21)00126-1.

    PMID: 34000246

This page explains basal cell carcinoma treatment options for informational purposes only and does not constitute medical advice. Your dermatologist and treatment team can recommend the safest approach for your tumor and priorities.